HOOK - Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today? | Benzinga
Gilead Sciences Inc (NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK) for approximately $21.25 million, at $1.4167 per share.
In addition, HOOKIPA has the right to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata participation in potential future equity raises.
The agreement with Gilead replaces the stock purchase agreement that Hookipa entered into with Gilead in ...